Wednesday, July 8, 2026

Drug profile · INN

ixabepilone

ixabepilone (IXEMPRA KIT) is a tubulin inhibitor. Route of administration: intravenous. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 1
Pipeline programs 2
News articles 0
Drug details — ixabepilone
US status
approved
Class
Route
INTRAVENOUS
Patents
1
Programs
2
Data quality
0.84

Quick answer

ixabepilone (IXEMPRA KIT) is a tubulin inhibitor. Route of administration: intravenous. Current US regulatory status: approved.

Key facts

INN ixabepilone
Brand IXEMPRA KIT
Mechanism Tubulin inhibitor
Target Tubulin
Route INTRAVENOUS
Formulation INJECTABLE

Mechanism of action

Tubulin inhibitor

Primary target: Tubulin

Approval history

Authority Status Date
FDA approved

Pipeline programs

  1. Ixabepilone + Capecitabine Phase 3 · Semnur Pharmaceuticals · Breast Cancer
  2. Ixabepilone Injection Phase 2 · Allarity Therapeutics · Metastatic Breast Cancer

Related & competitor drugs

  1. brentuximab vedotin Antineoplastic and immunomodulating agents (L01)
  2. cabazitaxel Antineoplastic and immunomodulating agents (L01)
  3. colchicine Musculo-skeletal system (M04)
  4. docetaxel Antineoplastic and immunomodulating agents (L01)
  5. paclitaxel Antineoplastic and immunomodulating agents (L01)
  6. vincristine sulfate Tubulin inhibitor

Related patents

  1. US 11421284

    Methods for predicting drug responsiveness in cancer patients

    Expires Mon Aug 18 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is ixabepilone?

ixabepilone (IXEMPRA KIT) is a tubulin inhibitor. Route of administration: intravenous. Current US regulatory status: approved.

What is the brand name for ixabepilone?

IXEMPRA KIT is a marketed brand name for ixabepilone. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of ixabepilone?

ixabepilone has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.